7-oxo-7H-benzimidazo[2,1-a]benz[de]isoquinoline-3-carboxylic acid | 52029-85-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 7-oxo-7H-benzimidazo[2,1-a]benz[de]isoquinoline-3-carboxylic acid
• 英文别名: 1,2-<4-Carboxy-naphthoylen-(1,8)>-benzimidazol；7-oxo-7H-benzo[de]benzo[4,5]imidazo[2,1-a]isoquinoline-4-carboxylic acid；7-Oxo-7H-benzimidazo[2,1-A]benzo[DE]isoquinoline-4-carboxylic acid；11-oxo-3,10-diazapentacyclo[10.7.1.02,10.04,9.016,20]icosa-1(19),2,4,6,8,12(20),13,15,17-nonaene-15-carboxylic acid
• CAS: 52029-85-3
• 化学式: C₁₉H₁₀N₂O₃
• 分子量: 314.3
• InChiKey: JGRDRFCADRXNEJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  24
• 可旋转键数：
  1
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  72.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  7-oxo-7H-benzimidazo[2,1-a]benz[de]isoquinoline-3-carboxylic acid 在 氯化亚砜 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 生成 11-Oxo-3,10-diazapentacyclo[10.7.1.02,10.04,9.016,20]icosa-1(19),2,4,6,8,12(20),13,15,17-nonaene-15-carboxamide
  参考文献：
  名称：

  COMPOSITION AND METHODS FOR THE TREATMENT OF CAMKK2-MEDIATED DISORDERS

  摘要：

  本公开提供了用于治疗哺乳动物眼部疾病的组合物和方法，特别是针对人类和小鼠，但不限于此。本公开还提供了使用这些新型小分子CaMKK2抑制剂治疗癌症和抑制食欲的方法。此外，这些衍生的组合物可以通过调节和抑制CaMKK2以及调节巨噬细胞介导的疾病来调节非眼部疾病，如癌症和抑制食欲。

  公开号：

  US20160229846A1
• 作为产物：
  描述：

  4-bromobenzo[d,e]benzo[4,5]-imidazo[2,1-a]isoquinolin-7-one 在 吡啶 、 硫酸 、 溶剂黄146 作用下， 以 水 为溶剂， 反应 49.0h， 生成 7-oxo-7H-benzimidazo[2,1-a]benz[de]isoquinoline-3-carboxylic acid
  参考文献：
  名称：

  COMPOSITION AND METHODS FOR THE TREATMENT OF CAMKK2-MEDIATED DISORDERS

  摘要：

  本公开提供了用于治疗哺乳动物眼部疾病的组合物和方法，特别是针对人类和小鼠，但不限于此。本公开还提供了使用这些新型小分子CaMKK2抑制剂治疗癌症和抑制食欲的方法。此外，这些衍生的组合物可以通过调节和抑制CaMKK2以及调节巨噬细胞介导的疾病来调节非眼部疾病，如癌症和抑制食欲。

  公开号：

  US20160229846A1

文献信息

• Composition and methods for the treatment of CaMKK2-mediated disorders
  申请人：Duke University

  公开号：US10336750B2

  公开（公告）日：2019-07-02

  The present disclosure provides compositions and methods for treating ocular disorders in mammals especially in and not limited to humans and mice. The present disclosure further provides methods of treating cancer and appetite suppression using the compositions which are novel small molecule inhibitors of CaMKK2. In addition, these derived compositions can regulate non-ocular disorders, such as cancer and appetite suppression by modulating and inhibiting CaMKK2 and the regulation of the macrophage mediated diseases.

  本公开提供了用于治疗哺乳动物眼部疾病的组合物和方法，特别是但不限于人和小鼠。本公开进一步提供了使用这些组合物治疗癌症和抑制食欲的方法，这些组合物是 CaMKK2 的新型小分子抑制剂。此外，这些衍生组合物可以通过调节和抑制 CaMKK2 以及调节巨噬细胞介导的疾病来调节非眼部疾病，如癌症和食欲抑制。
• SZADOWSKI, J.;STEC, B., PRZEM. CHEM., 1984, 63, N 10, 537-540
  作者：SZADOWSKI, J.、STEC, B.

  DOI：——

  日期：——
• METHODS AND COMPOSITIONS FOR DRUGS TO TREAT OPHTHALMIC DISEASES
  申请人：Duke University

  公开号：US20210198266A1

  公开（公告）日：2021-07-01

  The presently disclosed subject matter is directed to compositions and methods for treating CaMKK2-mediated ophthalmic diseases, including but not limited to 1) ocular surface inflammatory diseases (OSIDs), including but not limited to ocular graft versus host disease, ocular cicatricial pemphigoid, vernal keratoconjunctivitis, allergic eye disease, meibomian gland dysfunction, aqueous tear deficiency (common dry eye disease), corneal scarring, and conjunctival scarring and fibrosis; 2) uveitis and other inflammatory diseases of the eye, including but not limited to keratitis, scleritis, iritis, iridocyclitis, intermediate uveitis, pars planitis, posterior uveitis, choroiditis, chorioretinitis, retinitis, or panuveitis of noninfectious, infectious, or idiopathic etiologies; and 3) “back of the eye” retinal diseases, which include dry age-related macular degeneration, neovascular age-related macular degeneration, diabetic retinopathy, retinal vascular diseases (e.g. retinal vein occlusion, retinal artery occlusion), and retinal degenerations and dystrophies, in a subject. Particularly, the disclosed compounds exhibit improvements over STO-609, a well characterized specific inhibitor of CaMKK2. The disclosed compounds exhibit enhanced aqueous solubility and formulation, as well as elimination of non-binding isomers during production. The disclosed inhibitor compounds can be used to effectively treat ophthalmic diseases, cancers, appetite disorders, systemic inflammatory diseases, and the like.
• US9879005B2
  申请人：——

  公开号：US9879005B2

  公开（公告）日：2018-01-30
• [EN] METHODS AND COMPOSITIONS FOR DRUGS TO TREAT OPHTHALMIC DISEASES<br/>[FR] MÉTHODES ET COMPOSITIONS POUR MEDICAMENTS PERMETTANT DE TRAITER DES MALADIES OPHTHALMIQUES
  申请人：UNIV DUKE

  公开号：WO2020041344A1

  公开（公告）日：2020-02-27

  The presently disclosed subject matter is directed to compositions and methods for treating CaMKK2-mediated ophthalmic diseases, including but not limited to 1) ocular surface inflammatory diseases (OSIDs), including but not limited to ocular graft versus host disease, ocular cicatricial pemphigoid, vernal keratoconjunctivitis, allergic eye disease, meibomian gland dysfunction, aqueous tear deficiency (common dry eye disease), corneal scarring, and conjunctival scarring and fibrosis; 2) uveitis and other inflammatory diseases of the eye, including but not limited to keratitis, scleritis, iritis, iridocyclitis, intermediate uveitis, pars planitis, posterior uveitis, choroiditis, chorioretinitis, retinitis, or panuveitis of noninfectious, infectious, or idiopathic etiologies; and 3) "back of the eye" retinal diseases, which include dry age-related macular degeneration, neovascular age-related macular degeneration, diabetic retinopathy, retinal vascular diseases (e.g. retinal vein occlusion, retinal artery occlusion), and retinal degenerations and dystrophies, in a subject. Particularly, the disclosed compounds exhibit improvements over STO-609, a well characterized specific inhibitor of CaMKK2.